It causes a p. A165T variation in MARC1 and is associated with a milder form of MASLD, lower levels of aminotransferase/alanine aminotransferase, and a lower risk of cirrhosis (Emdin et al., 2020; Luukkonen et al., 2020). Here, MTARC1 is linked to metabolic dysfunction-associated steatotic liver disease.